FDA
-
-
-
-
-
-
-
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
-
-
-
-
-
-
-
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
-
-
-
-
-
-
-
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer wit
-
-
-
-
-
-
-
Morgan Stanley Upgrades Roche Holding (ROG:SW) (RHHBY) to Equalweight
-
-
-
-
-
-
-
Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories
-
-
-
-
-
-
-
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
-
334,691 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
